Top videos
Source ABC7, 24 November 2009 An initial single-arm Phase II trial (ACT II) has reported promising preliminary data in 23 patients who received CDX-110 vaccine. Median time to disease progression was 16.6 months and estimated median overall survival was 33.1 months. This compared favorably with data for a historical control group in which median time to progression was 6.4 months and median overall survival was 15.2 months. The study was sponsored by Celldex Therapeutics Inc. of Phillipsburg, NJ
There is no sure way for women to avoid their most common type of cancer. But when breast cancer is found early, the survival chances are the greatest. Here is October’s survivor story:
It has been 25 years since a woman very dear to us here at CBS 11 News found out she was a living cliché. Following in her birth mother’s footsteps, she discovered breast cancer on her own. Today she’s alive, urging every woman she can reach to do a self-check.
We here at CBS 11 News have come to know Juneil Jones-Flemming’s soft, warm greeting.
Some of you may have too
Revision knee replacement is peformed by Dr.Venkatachalam for lack of mobility. Infection. aseptic loosening are frequent causes requiring a revision. Madras Joint replacement center performs primary and revision knee replacements in a super specialty hospital in Chennai, India. Dr.Venkatachalam, the chief orthopedic surgeon is UK board certified.